Naïve human embryonic vascular progenitor cells and methods of treatment
AssigneeThe Johns Hopkins University
InventorsElias Zambidis, Tea Soon Park
Life of this patent
Estimating the term…
Abstract
Compositions are provided compositions comprising tankyrase/PARP (poly-ADP-ribose polymerase, also known as poly-ADP-ribosyltransferase) inhibitor-regulated naïve human induced pluripotent stem cells (N-hiPSCs) and their use in the treatment of vascular disorders.
Claims21
A method of treating an ischemic retina of a subject in need thereof, comprising:
- administering to the subject, a composition comprising an effective amount of the naïve human induced pluripotent stem cells (N-hiPSC), wherein the N-hiPSC differentiate and revascularize the subject's ischemic retina, thereby treating the ischemic retina,
- wherein the N-hiPSC are obtainable by steps comprising contacting a human induced pluripotent stem cell (hiPSC) with a composition comprising a leukemia inhibitory factor (LIF) and at least one or more agents which inhibit one or more signaling pathways to produce the N-hiPSC.
A method of treating an ischemic retina of a subject in need thereof, comprising:
- contacting a human induced pluripotent stem cell (hiPSC) with a composition comprising a leukemia inhibitory factor (LIF) and at least one or more agents which inhibit one or more signaling pathways to produce a naïve human induced pluripotent stem cell (N-hiPSC);
- administering to the subject, a composition comprising an effective amount of the naïve human induced pluripotent stem cells (N-hiPSC), wherein the N-hiPSC differentiate and revascularize the subject's ischemic retina, thereby
- treating the ischemic retina.
A method of producing a vascular progenitor (VP) cell comprising:
- contacting a human induced pluripotent stem cell (hiPSC) with a composition comprising a leukemia inhibitory factor (LIF) and at least one agent or a simultaneous combination of at least three agents which inhibit one or more signaling pathways to produce a naïve human induced pluripotent stem cell (N-hiPSC);
- and,
- differentiating the N-hiPSC in vitro or by implantation in vivo.
18-25. (canceled)
A composition comprising an effective amount of naïve human induced pluripotent stem cells (N-hiPSCs) wherein the N-hiPSCs are tankyrase inhibitor regulated.
28-29. (canceled)
Dependencies are inferred from the claim text.